Committed to making the difference
AiCuris is a pharmaceutical company specializing in the discovery, research, and development of novel, resistance‐breaking antiviral and antibacterial agents for the treatment of serious and potentially life-threatening infectious diseases. Founded in 2006 as a spin‐out from Bayer Infection Research, AiCuris today manages an innovative pipeline of anti-infective agents with a team of internationally recognized scientists in Research and Development. We are one of the few European biotech companies which has brought a drug with “block buster” potential to the market (Prevymis® 2017/18).
AiCuris expands its Management
AiCuris expands its Management with Prof. Dr. Hubert Trübel joining as Chief Medical Officer and the Appointment of Dr. Tamara Pfaff, Head of Preclinical Development, to the Management Team
AiCuris changes its legal form
AiCuris Anti-infective Cures GmbH becomes AiCuris AG, the German legal form of a stock corporation, to prepare for future growth.
AiCuris joins German initiative BEAT-COV
The Biotech Emergency Alliance for Therapies against COVID-19 (BEAT-COV) initiative asks for political and financial support to develop and produce novel and innovative COVID-19 therapeutics.